Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a rare sarcoma has also been pushed back.
Hemlibra has taken a bite out of Shire's FEIBA sales, but compensatory boosts in other areas of the business helped CEO Ørnskov keep the business ticking over while awaiting the finalization of Takeda's takeover.
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
GSK once again provided grist to the stock market rumor mill over the weekend, with reports emerging that its chairman has been talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?